ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 03, 2023 11:01 JST
Source:
Ocumension Therapeutics
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202
HONG KONG, Feb 03, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully.
The phase I clinical trial of OT-202 was designed as a randomized, double-masked, placebo-controlled clinical trial on the safety, tolerance and pharmacokinetic properties of its single/multiple administration on healthy adult subjects in China.
Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "OT-202 (tyrosine kinase inhibitor) is a class I innovative drug developed by the Company for the treatment of moderate to severe dry eye. A total of 30 subjects were enrolled for the phase I clinical trial in China. OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial. Currently, we are in the process of advancing the study for the phase II clinical trial."
The mechanism of action of OT-202 is that the dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response.
More information about Ocumension Therapeutics:
https://www.ocumension.com/
Source: Ocumension Therapeutics
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
Feb 07, 2025 04:00 JST
MHI Thermal Systems to Launch New Model of the "Ene-Conductor" Heat Source Control System
Feb 06, 2025 16:51 JST
Hitachi establishes its fourth Corporate Venture Capital Fund to capture technology turning points and future growth opportunities
Feb 06, 2025 16:32 JST
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier
Feb 05, 2025 17:46 JST
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 05, 2025 13:59 JST
Toyota to Form Comprehensive Partnership on Carbon Neutrality with Shanghai and Establish a Company to Develop and Produce BEVs and Batteries
Feb 05, 2025 13:56 JST
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 05, 2025 10:25 JST
TOYOTA GAZOO Racing Launches Evolved GR Corolla in Japan
Feb 04, 2025 18:41 JST
Mitsubishi Heavy Industries Achieves Double-Digit Order Intake and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 04, 2025 18:34 JST
MAZDA TRANS AOYAMA Opens in Minami-Aoyama
Feb 04, 2025 17:38 JST
Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planning
Feb 04, 2025 11:39 JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Feb 03, 2025 17:23 JST
MHI Group Presents "Best Innovation 2024" Awards for Products and Activities that Contribute to Solving Social Issues
Feb 03, 2025 14:31 JST
Fujitsu and Tokai National Higher Education and Research System leverage explainable AI to enhance space weather prediction in collaboration with JAXA
Feb 03, 2025 12:05 JST
Enjoy Anime Tokyo Station in the Metaverse! ANIME TOKYO STATION ON ROBLOX Opens at 3:00 p.m. on January 31, 2025!
Feb 01, 2025 08:00 JST
DENSO Announces Third Quarter Financial Results
Jan 31, 2025 18:09 JST
Rally Driver Hiroshi Masuoka Receives the Person of Sports Merit Award in Japan
Jan 31, 2025 15:12 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Launches Visi Fine(R): A Group of Precious Metal Materials for Medical Device Components
Jan 31, 2025 11:00 JST
Mazda Production and Sales Results for December 2024 and for January through December 2024
Jan 30, 2025 16:44 JST
Lexus Announces Global Sales Results for 2024
Jan 30, 2025 15:52 JST
More Latest Release >>
Related Release
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema
December 20 2023 20:51 JST
Ocumension Therapeutics Announces 2023 Interim Results
August 24 2023 23:35 JST
Ocumension Therapeutics Announces 2022 Annual Results
March 30 2023 22:29 JST
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
March 13 2023 18:30 JST
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results
February 14 2023 10:57 JST
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China
February 01 2023 10:00 JST
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively
January 30 2023 11:38 JST
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
March 20 2021 10:10 JST
More Press release >>